ASH 2023 | AML differentiation state & genotype influence anti-apoptotic protein expression & ven sensitivity
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses genotypic and phenotypic resistance mechanisms to venetoclax (ven) in acute myeloid leukemia (AML). Both myeloid differentiation and genetic mutations independently drive anti-apoptotic protein expression, with cell differentiation state emerging as the more potent driver. There is also an interaction between genotype and phenotype, with a higher expression of resistance-related mutations in specific AML cell phenotypes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
